- Report
- October 2024
- 181 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- March 2025
- 186 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- October 2024
- 186 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- October 2024
- 188 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- April 2024
- 140 Pages
Global
From €2847EUR$2,999USD£2,402GBP
- Report
- March 2025
- 93 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 194 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- February 2025
- 168 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- August 2024
- 175 Pages
Global
From €4747EUR$5,000USD£4,004GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- July 2024
- 105 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- July 2024
- 100 Pages
Global
From €3560EUR$3,750USD£3,003GBP
- Report
- November 2024
- 150 Pages
Global
From €4604EUR$4,850USD£3,884GBP
- Report
- September 2024
- 150 Pages
Global
From €4604EUR$4,850USD£3,884GBP
- Report
- May 2024
- 200 Pages
Global
From €3940EUR$4,150USD£3,323GBP
- Report
- May 2024
- 130 Pages
United States
From €5649EUR$5,950USD£4,765GBP
- Report
- August 2024
- 130 Pages
North America
From €3797EUR$4,000USD£3,203GBP
- Report
- May 2023
- 150 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- October 2023
- 190 Pages
Global
From €4272EUR$4,500USD£3,603GBP

Iodine-131 (I-131) is a radioactive isotope of iodine used in nuclear medicine and radiopharmacology. It is used to diagnose and treat a variety of conditions, including thyroid cancer, hyperthyroidism, and Graves' disease. I-131 is also used to treat certain types of cancer, such as lymphoma and neuroblastoma. It is administered orally, intravenously, or by inhalation. The radiation emitted by I-131 is absorbed by the body and used to destroy cancer cells.
I-131 is produced in nuclear reactors and cyclotrons. It is then purified and formulated into a variety of products, such as capsules, solutions, and suspensions. These products are then distributed to hospitals, clinics, and other healthcare facilities.
The I-131 market is highly regulated, with strict safety and quality standards in place. The market is also subject to fluctuations in supply and demand, as well as changes in the cost of production.
Some companies in the I-131 market include GE Healthcare, Mallinckrodt Pharmaceuticals, Jubilant Radiopharma, and Bracco Diagnostics. Show Less Read more